# Enthera Srl

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/enthera

- Industry: Biotechnology
- Headquarters: Milan, Italy
- Website: www.entherapharmaceuticals.com
- Total disclosed funding: $46M
- Latest round: Series A (Jan 28, 2021)
- Investors on record: 8

## About

Based in Milan, Italy, and founded in 2016 by co-founder Francesca D'Addio, Gabriella Camboni, and Paolo Fiorina operates as a biotech company developing disease-modifying biologics. In March 2018, Enthera Srl announced that it has entered into a license agreement for The Trianni Mouse™, a best-in-class monoclonal antibody discovery platform. In January 2021, the company raised its latest series A funding, with total financing of EUR 7 million from Roche Venture Fund.

The company is a biotech company that offers a pipeline of class biologics for autoimmune conditions and focuses on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD). Enthera Srl also develops disease-modifying treatments by preserving and re-establishing cell and organ function to revert the outcome of diseases.

## Funding rounds

- Series A, Jan 28, 2021, $8.5M — Roche Venture Fund
- Series A, Jul 28, 2020, $33M — Sofinnova Partners, AbbVie Ventures, Banca Profilo, JDRF T1D Fund, Indaco Venture Partners, BANOR SIM SpA
- Seed, Jul 24, 2018, $4.7M — Sofinnova Partners, BiovelocITA S.r.l, JDRF T1D Fund

## Investors

- Sofinnova Partners (https://capitalatlas.ai/funds/sofinnova-partners) — Seed, Series A
- BiovelocITA S.r.l — Seed
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Seed, Series A
- AbbVie Ventures (https://capitalatlas.ai/funds/abbvie-ventures) — Series A
- Banca Profilo — Series A
- Indaco Venture Partners (https://capitalatlas.ai/funds/indaco-venture-partners) — Series A
- BANOR SIM SpA — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A